Accelerate Diagnostics, Inc - רווח נקי למניה בארבעת הרבעונים האחרונים AXDX

The modernization of assembly lines and the robotization of calibration promise an increase in product quality. This chart on GURU.Markets shows that the annual earnings per share growth (TTM) for Accelerate Diagnostics (AXDX) currently stands at 37.30, reflecting the current level of the metric. Accelerate Diagnostics (AXDX) generates revenue through the sale of pathogen identification systems and cartridges, leveraging hospital demand for the Accelerate Pheno platform and M&A potential.

Fundamental asset screening begins with an analysis of profit generation efficiency. This indicator captures the percentage change in earnings per share over a rolling twelve-month period. The EPS YoY TTM growth trajectory allows for a real-time assessment of business scaling rates. For Accelerate Diagnostics (AXDX), this metric reflects financial stability within its sovereign product cycle. The independence of medical developments from macroeconomic factors transforms profit dynamics into a reliable signal of a defensive asset.